BridgeBio Pharma, Inc.
BBIODrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 3 past
No catalysts found.
How BBIO's past catalysts played out
Acoramidis
Amyloidosis
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
AG10
Familial ATTR-CM (ATTRm-CM, or FAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis | Phase 3 | Amyloidosis | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
AG10 | Phase 2 | Familial ATTR-CM (ATTRm-CM, or FAC) | - | - |
Frequently asked questions
What is in BridgeBio Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in BridgeBio Pharma, Inc.'s (BBIO) pipeline across Phase 3, Phase 2. Its lead program is Acoramidis (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Pharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BridgeBio Pharma, Inc. (BBIO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BBIO biotech catalysts?→
Add BBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.